Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for Active Anal Fistulas in Crohn's Disease
NCT06902987Phase 1Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of upadacitinib in Crohn's disease, sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoints: Clinical response of anal fistula at 12 weeks and Imaging remission of anal fistula at 12 weeks. Started Jan 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06902987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902987.